Vanda Pharmaceuticals price target raised to $17 from $14 at B. Riley

B. Riley raised the firm’s price target on Vanda Pharmaceuticals (VNDA) to $17 from $14 and keeps a Buy rating on the shares. Following BYSANTI’s approval, the firm’s revenue model for Vanda has been updated, reflecting expected growth in the psychiatry franchise with peak BYSANTI sales now included and probability adjustments removed, the analyst tells investors in a research note. Base assumptions include mid-to-high single-digit quarter over quarter growth in BYSANTI/FANAPT prescriptions through 2026, t ...